Background: Protein mono-ADP-ribosylation is a reversible post-translational modification that modulates the function of target proteins. The enzymes that catalyze this reaction in mammalian cells are either bacterial pathogenic toxins or endogenous cellular ADP-ribosyltransferases. The latter include members of three different families of proteins: the well characterized arginine-specific ecto-enzymes ARTCs, two sirtuins and, more recently, novel members of the poly(ADPribose) polymerase (PARP/ARTD) family that have been suggested to act as cellular mono-ADP-ribosyltransferases. Here, we report on the characterisation of human ARTD15, the only known ARTD family member with a putative C-terminal transmembrane domain.
Introduction
Mono-ADP-ribosylation is a covalent, post-translational modification catalysed by bacterial toxins and eukaryotic ADPribosyltransferases. These enzymes transfer the ADP-ribose moiety from ß-NAD+ to specific amino acids of various cellular acceptor proteins, and as a consequence affect their biological function [1, 2, 3] . ADP-ribosylation was originally identified as the pathogenic mechanism of certain bacterial toxins: the diphtheria, cholera, pertussis and clostridia toxins are in fact mono-ADPribosyltransferases known to cause various pathologies as a consequence of their translocation into mammalian host cells [4, 5] . In mammals, enzymes structurally and functionally related to these toxins have been identified and characterized as intracellular or extracellular ADP-ribosyltransferases (ART) [2, 6] . These two groups of mammalian ARTs are defined as ARTC (Clostridia-toxin-like) and ARTD (Diphtheria-toxin-like), respectively [7] . The ARTC family includes glycosylphosphatidylinositol (GPI)-anchored and secreted enzymes that lead to extracellular mono-ADP-ribosylation [6, 8, 9] . Four different human ARTCs have been identified (ARTC1, 3, 4, 5) of which ARTC1 and ARTC5 are active enzymes that modify the arginine residues of secreted and plasma membrane-associated proteins, such as human neutrophil protein 1 (HNP1) and integrin-a7 [10, 11, 12] . Intracellular targets of mono-ADP-ribosylation have also been described [13, 14, 15] , but only in one case (glutamate dehydrogenase; GDH) has the enzyme involved actually been identified: SirT4 [16] . This enzyme mono-ADP-ribosylates mitochondrial GDH thus repressing its activity [16] and consequently regulating insulin secretion in pancreatic ß cells. SirT4 is a member of a third NAD+-using family of proteins, the sirtuins, which encode protein deacetylases [17, 18] . The mammalian mono-ADP-ribosyltransferases responsible for intracellular mono-ADP-ribosylation are only now beginning to be identified. In addition to the sirtuins SirT4 and SirT6, novel members of the poly-ADP-ribose polymerase (PARP/ARTD) family are also being implicated in intracellular mono-ADP-ribosylation [2, 19, 20] . The human ARTD family includes six members (ARTD1-6), which are typical poly-ADP-ribosyl polymerases and eleven novel poorly characterized members (ARTD7-17) [19, 20] . The typical PARPs can transfer multiple ADP-ribose residues, and even branched polymers of ADP-ribose, onto their target proteins, thus regulating DNA repair, apoptosis and chromatin dynamics [19] . PARP1/ ARTD1, the founding member of this family, acts as a molecular sensor of DNA breaks and plays a key role in the spatial and temporal organisation of their repair [21, 22] . It catalyzes both intermolecular auto-modification and hetero-modification of histones or proteins involved in DNA synthesis and repair [21, 22, 23] . PARP/ARTD 2-6, are also poly-ADP-ribosyl polymerases involved in DNA repair (ARTD2 and ARTD3), regulation of telomere length (ARTD5 and ARTD6), spindle pole function (ARTD3, ARTD5 and ARTD6) and genotoxic response (ARTD4) [24, 25, 26, 27, 28] . These polymerases are characterised by the H-Y-E triad of amino-acid residues in the catalytic domain, while the most recently identified members, ARTD7 to ARTD17, feature variations of this motif and are unlikely to promote the formation of ADP-ribose polymers, despite the overall similarity of the catalytic domain [19, 20] . Some of these enzymes have been proposed to act as cellular mono-ADP-ribosyltransferases, and indeed this has been demonstrated for ARTD10 [29] . Little is known concerning the biological roles of these enzymes, and only fragmented information has been obtained during recent years [30, 31, 32, 33, 34, 35] .
Karyopherin-ß1/importin-ß1 (Kapß1, uniprot ID Q14974) plays a pivotal role in the shuttling of proteins with nuclear localisation signals (NLSs), between the cytosol and the nucleus, through the nuclear pore complex (NPC) [36, 37, 38] . During this process, Kapa (karyopherin-a/importin-a), binds to the NLS, whereas Kapß1 binds directly to Kapa, leading to the formation of a tri-molecular complex [39, 40, 41] . The complex tethers to, and passes through the NPC by Kapß1 binding to the nucleoporins. Once in the nucleoplasm, the complex releases the cargo protein, and Kapß1 and Kapa are exported back to the cytosol to reinitiate a new import cycle [37, 38] . In addition to its role in nuclear transport, Kapß1 has also been shown to participate in regulating mitotic spindle formation [42, 43] . Specifically, Kapß1 acts as a negative regulator of NuMA and TPX2, two microtubule-associated proteins involved in the organisation of the mitotic spindle [44, 45] .
Here we report on the characterization of human PARP16/ ARTD15 (herein referred to simply as ARTD15), the only known member of the family that does not contain recognizable accessory domains beyond the catalytic one. ARTD15 is a 36-kDa protein containing a predicted C-terminal transmembrane tract, but no information was available concerning its intracellular localisation and biochemical properties. We now show that ARTD15 is an endoplasmic reticulum-associated type IV enzyme with mono-ADP-ribosyltransferase activity, able to interact with, and mono-ADP-ribosylate the nuclear transport factor Kapß1.
Results

ARTD15 is Expressed in Numerous Human Cell Lines
ARTD15 with its predicted 323 amino acids is the smallest member of the PARP/ARTD family. Unlike other ARTDs, ARTD15 does not contain recognizable accessory domains and only features the catalytic domain (Fig. 1A) .
We first determined if the ARTD15 gene was transcribed in various cell lines by quantitative real-time PCR (qRT-PCR). The highest mRNA levels were found in HEK293 and HeLa cell lines (Fig. 1B) . Some of these cell lines were further analysed for protein expression using an antibody raised against ARTD15 (Fig. 1C,  top; Fig. 1D ). The protein expression levels of endogenous ARTD15 were measured relative to those in HEK293 (Fig. 1C,  bottom panel) . This is the first evidence that ARTD15 is transcribed and that the protein is ubiquitously expressed.
ARTD15 is a Transmembrane Protein That Localises to the Endoplasmic Reticulum
ARTD15 is the only PARP/ARTD family member with a predicted C-terminal transmembrane (TM) domain (S288-I308; Fig. 1A ). To investigate the cellular localisation of human ARTD15 we analyzed both endogenous (Fig. 1E ) and overexpressed ( Fig. 2A) protein by immunofluorescence. A clear perinuclear staining of endogenous ARTD15 and its co-localization with the endoplasmic reticulum (ER) protein disulfide isomerase (PDI) is shown in Figure 1E . Next, we generated an N-terminus FLAG-tagged ARTD15 (FLAG-ARTD15), and transiently expressed it in HeLa cells that were then analyzed by immunofluorescence, immuno-electron microscopy (EM) and Western blotting. Immunofluorescence images confirmed peri-nuclear ARTD15 localisation ( Fig. 2A) , while there was no detectable FLAG staining in mock-transfected cells. Moreover, overexpressed ARTD15 co-localised with the ER proteins calnexin and PDI ( Fig. 2A ), but not with markers of other intracellular compartments, such as the Golgi complex, mitochondria and microtubules ( Fig. 2A) . Immunogold labelling and electron microscopy confirmed ARTD15 localisation to ER and further highlighted the association with tubular ER structures and to the nuclear envelope (Fig. 2B ). These results demonstrate that ARTD15 resides in the ER.
To further investigate the intracellular localization of ARTD15, we generated a deletion mutant lacking the region encompassing the putative transmembrane domain (aminoacids 278-322; FLAG-DTM-ARTD15). FLAG-ARTD15 and FLAG-DTM-ARTD15 were thus transiently expressed in HeLa cells and the sub-cellular localisation of the mutated proteins analyzed by immunofluorescence (Fig. 3A) . FLAG-DTM-ARTD15 showed a diffuse, cytosolic localization compared with full length ARTD15 (Fig. 3A ). The cytosolic localization was then confirmed by Western Blot analysis (Fig. 3B) , which confirmed that FLAG-DTM-ARTD15 was confined to the cytosolic fraction as opposed to the full length protein, which was found in total membranes (Fig. 3B) . Altogether, these results demonstrate that the C-terminal region, containing the predicted transmembrane domain, is necessary and sufficient for the localisation of ARTD15 to ER membranes.
To analyse the orientation of ARTD15, we applied a trypsin protease-protection assay (see Materials and Methods). To this end we generated N-terminal and C-terminal GFP-tagged ARTD15 fusion protein. HeLa cells were transiently transfected with these constructs and were either left untreated (control), or incubated with digitonin to permeabilise the plasma membrane, or with Triton X-100 to solubilise all cellular membranes. Cells were then treated with trypsin, lysed, and finally analyzed by WB using an anti-GFP antibody to reveal ARTD15 and two antibodies directed against either the N-or C-terminus of calnexin (as a control). Calnexin is a well-characterised ER type I transmembrane domain protein with its N-terminal end facing the lumen and the Cterminal portion in the cytoplasm [46] . As expected, the Cterminal of calnexin was no longer detected when trypsinised after digitonin permeabilisation, whereas its N-terminus was lost only after Triton X-100 solubilisation, which allows trypsin to enter the ER lumen ( Fig. 3C; calnexin) . In the case of ARTD15 instead, trypsinisation resulted in the loss of its N-terminal end after mild permeabilisation with digitonin ( Fig. 3C; ARTD15) . Thus the Nterminus of ARTD15 is exposed to the cytoplasm, whereas its Cterminus faces the ER lumen. Altogether, these data demonstrate that, as opposed to calnexin, ARTD15 is a single pass transmembrane protein with the N-terminal region (aa. 1-280) positioned toward the cytoplasm, and the very short C-terminal tail (aa. 300-322) facing the ER lumen (Fig. 3D) . These results define ARTD15 as a tail-anchored (type IV) protein.
ARTD15 is a Mono-ADP-ribosyltransferase
The ARTD family members that lack conserved residues crucial for ADP-ribose polymer elongation have been proposed either to be inactive enzymes (ARTD9 and ARTD13) or to act as mono-ADP-ribosyltransferases. We thus analyzed whether ARTD15 was indeed an active enzyme.
To this end, we purified GST-ARTD15 from Escherichia coli. The recombinant GST-ARTD15 was tested in an in vitro ADPribosylation assay using [
32 P]-NAD. A main 50-kDa band, corresponding precisely to the molecular weight of purified GST-ARTD15 was detected (Fig. 4A ). Thus, ARTD15 is able to catalyse its auto-ADP-ribosylation, a feature typical of all ARTC and ARTD enzymes. The GST-ARTD15 Km value for NAD was evaluated and found to be 290+/247 mM, with a calculated Vmax of 0,7 pmole/h/mg of purified protein (Fig. 4B) . To verify the specificity of this auto-modification, we generated a double GST-ARTD15 H152A/Y254A mutant (ARTD15-dm; H152 is involved in NAD binding and Y254 is the predicted catalytic amino acid). Figure 4C shows that the ARTD15-dm completely lacks the catalytic activity, as compared to the wild type protein. In conclusion, ARTD15 is an active enzyme that can catalyse its auto-ADP-ribosylation.
Next, we evaluated the activity of ARTD15 in mammalian cells by analysing both its ability to hydrolyse [ 32 P]-NAD and to transfer the ADP-ribose moiety to agmatine, a well-known model substrate for arginine-specific mono-ADP-ribosylation (ARTC1). To this end, HeLa cells were transiently transfected with ARTD15; total cell membranes were then prepared and incubated with [
32 P]-NAD in the absence or presence of 1 mM agmatine. The supernatants were analysed by TLC to monitor the hydrolysis of the [ 32 P]-NAD. Figure 4D shows that ADP-ribose is generated when [
32 P]-NAD was incubated with a NAD-glycohydrolase (NADase) (control; Fig. 4D left panel, NADase lane) but not when incubated with ARTD15 ( Fig. 4D left panel, ARTD15 lane). As expected, agmatine was ADP-ribosylated by ARTC1 ( Fig. 4D right panel), but not by ARTD15 (Fig. 4D, right panel) . This implies that ARTD15 is an active enzyme, which however does not catalyse ADP-ribosylation on arginine; furthermore ARTD15 does not feature NADase activity per se and thus cannot affect NAD catabolism. In line with these conclusions, ARTD15 [ 32 P]-ADP-ribosylation was not affected by the arginine-specific mono-ADP-ribosyltransferase inhibitor MIBG [47] , as instead was the ADP-ribosylation of the Gß subunit, a well characterized target of arginine-specific mono-ADP-ribosyltransferases [2, 48, 49] (Fig. 4E) .
To gain further insight as to which ARTD15 amino acid is modified by ADP-ribosylation, we investigated the chemical stability of the ADP-ribosyl linkage. NH 2 OH treatment for 12 h (which hydrolyzes the ADP-ribosylated arginine [14, 50, 51, 52] ) did not remove the ADP-ribose of [ 32 P]-ADP-ribosylated ARTD15 (Fig. 4F, lane 3) ; this is in agreement with the fact that ARTD15 is unable to modify agmatine (Fig. 4D, right panel) and that its activity is not inhibited by MIBG (Fig. 4E) . The same experiment also ruled out the possibility that the ADP-ribose is linked to glutamate since a 20-min NH 2 OH treatment (normally sufficient to hydrolyze glutamate-linked ADP-ribose) did not remove ADPribose from ARTD15. Finally, treatment of [
32 P]-ADP-ribosylated ARTD15 with HgCl 2 (which would act on ADP-ribosylated cysteine) was also ineffective. We did observe a 50% loss of label upon HCl treatment (Fig. 4F, lane 4) , which is known to be effective on ADP-ribosylated serine/threonine residues [53] .
Altogether, these data demonstrate that ARTD15 is an active member of the PARP family, with auto-catalytic activity; however, at variance with classical mono-ADP-ribosyltransferases it does not appear to target arginine or cysteine amino acid residues. Moreover, as opposed to PARP enzymes, ARTD15 is unable to transfer ADP-ribose onto glutamate. The specific aminoacid targeted by ARTD15 remains to be established.
ARTD15 Interacts with Kapß1
Having provided evidence that ARTD15 is an active ADPribosyltransferase, we searched for possible interactors. To this end HEK293 cells were transiently transfected with a plasmid encoding for N-terminal tagged FLAG-ARTD15 or empty vector. Total lysates from these cells were immuno-precipitated with an anti-FLAG antibody (Fig. 5A) . Two bands in the ARTD15 sample, with a molecular mass of 36 and 96 kDa, as revealed by silver staining (Fig. 5A) were identified by MALDI-TOF-MS analysis as ARTD15 itself and Kapß1 (Table 1 ). The same result was also obtained in HeLa cells (not shown). We validated the interaction between ARTD15 and Kapß1 by co-immunoprecipitation. Total lysates from HeLa cells that had been transiently transfected with FLAG-ARTD15 were incubated with anti-Kapß1 antibody (Fig. 5B) . Under these conditions, ARTD15 was coimmunoprecipitated with endogenous Kapß1, demonstrating that Kapß1 is an ARTD15 interactor in intact cells. We could not detect co-immunoprecipitation of endogenous ARTD15, possibly due to the low levels of endogenous ARTD15.
To verify whether the interaction between ARTD15 and Kapß1 was direct, we applied a pull down assay using purified proteins. Increasing concentrations of Kapß1 were incubated with either GST-ARTD15 or GST alone as a control (Fig. 5C ). Under these conditions, Kapß1 specifically interacted with GST-ARTD15 in vitro, providing evidence of a novel physical interaction between ARTD15 and Kapß1.
Finally, we evaluated this interaction in intact cells by immunofluorescence. HeLa cells were probed with antibodies against ARTD15 and Kapß1. Fig. 5D shows that indeed endogenous ARTD15 and Kapß1 co-localised, suggesting that Kapß1 most likely interacts with the cytosolic portion of membrane bound ARTD15.
Kapß1 is a Target of ARTD15-mediated Mono-ADPribosylation
The finding that ARTD15 and Kapß1 are interacting partners, prompted us to investigate whether Kapß1 can be ADPribosylated by ARTD15. The enzymatic activity of ARTD15 towards Kapß1 was evaluated in an in vitro ADP-ribosylation assay using recombinant proteins. His-Kapß1 was incubated with or without GST-ARTD15 in the presence of 10 mM [ 32 P]-NAD (Fig. 6A ). Under these experimental conditions recombinant Kapß1 was specifically labelled only when incubated with ARTD15 (Fig. 6A) . Thus, ARTD15 can ADP-ribosylate Kapß1. Moreover, His-Kapß1 ADP-ribosylated with biotinylated NAD was pulled-down with GST-ARTD15. We found that a similar percentage (ca 50%) of both unmodified His-Kapß1 and ADPribosylated His-Kapß1 interacted with ARTD15. To confirm that Kapß1 modification is a mono-ADP-ribosylation, and not a poly-ADP-ribosylation, we analyzed the length of the ADP-ribose chain bound to both ARTD15 and Kapß1 following a described procedure [54] . To this end, purified ARTD15 and Kapß1 were ADP-ribosylated as described above. The nucleotide fraction bound to the protein was separated by TBE-PAGE, with [ 32 P]-NAD and [
32 P]-ADP-ribose used as reference standards (Fig. 6B ). We found that the nucleotide fractions released from Kapß1 (lane 2-3) and from ARTD15 (lane 4) co-migrate with the single unit of ADP-ribose obtained from mono-ADP-ribosylated agmatine (lane 6), thus confirming that the ARTD15-catalysed reactions (both auto-and hetero-modifications) are very likely mono-and not poly-ADP-ribosylation events. ARTD15-mediated Kapß1 mono-ADPribosylation was further investigated making use of ADP-ribosylation inhibitors. Since we already knew MIBG to be ineffective, we tested the effects of PJ34, a well-characterized inhibitor of ARTD enzymes [55] , and found that ARTD15 auto-modification and Kapß1 mono-ADP-ribosylation were both inhibited (Fig. 6C) . Finally, the ability of ARTD15 to catalyze Kapß1 mono-ADPribosylation was also evaluated using isolated membranes, obtained from HeLa cells that had been previously transfected with ARTD15. Figure 6D shows that in the presence of ARTD15 a 96 kDa protein was specifically labelled. This same protein was recognized by an anti-Kapß1 antibody. We knocked-down endogenous ARTD15 in HeLa cells by siRNA and achieved a 70% decrease in ARTD15 levels; as a consequence, Kapß1 labelling decreased 45+/212% (Fig. 6E) . Altogether, these data confirm that ARTD15 and Kapß1 interact and that Kapß1 is specifically mono-ADP-ribosylated by ARTD15.
Discussion
Here we report on the characterization of human ARTD15, unveiling a novel intracellular mono-ADP-ribosyltransferase. Endogenous mono-ADP-ribosylation is believed to have important roles in cellular signalling and regulation, however the enzymes responsible for this intracellular mono-ADP-ribosylation remain elusive and are only now beginning to be identified.
The human genome encodes 17 poly-ADP-ribose-polymerase (PARP)-like genes. Many of these PARP-like proteins (ARTDs according to the new nomenclature) however, are unlikely to carry out genuine ADP-ribose polymer formation; this is because although they do have a catalytic domain similar to that of ARTD1/PARP1, they lack the catalytic glutamate residue critical for polymerase activity [19, 20, 56] . A number of ARTDs (ARTD7, ARTD8 and ARTD12) have been proposed instead to act as cellular mono-ADP-ribosyltransferases [57] , although only for ARTD10 has this been formally demonstrated [29] . This raises the possibility that other members of the PARP/ARTD family are intracellular mono-ADP-ribosyltransferases.
Here we show for the first time that ARTD15 is a bona fide mono-ADP-ribosyltransferase that catalyse auto-and heteromodification by transfer of a single ADP-ribose moiety. ARTD15 has a Km for NAD around 290 mM for its own ADP-ribosylation, a value compatible with the intracellular NAD levels (ca. 500 mM). If we consider that these estimates were obtained in a reconstituted setting with the purified protein, it is conceivable that in physiological conditions kinetic parameters might be more favourable and affinity for NAD higher.
Of note, when we performed an in vitro ADP-ribosylation assay using total membranes obtained from cells over-expressing ARTD15, hetero-modification was the largely preferred reaction.
We also show that ARTD15 is a ubiquitous protein and appears to be the first ADP-ribosyltransferase known to be associated with the ER. While typical PARP enzymes are mainly nuclear, the most recently identified members are emerging as proteins having a mostly extra-nuclear localisation, as is the case of ARTD7, ARTD8 and ARTD12. These are cytosolic proteins that have been specifically identified as stress granule components, although their cellular functions and targets remain unknown [57] . An additional feature of ARTD15 is that it is the only ARTD family member with a carboxy-terminal transmembrane domain and an amino-terminal cytosolic catalytic domain. This orientation is shared with other known tail-anchored (TA) proteins and confirms a predictive bioinformatics study [58] . Several important protein families are TA-proteins, including the SNAREs, which mediate intracellular transport vesicle tethering, and the apoptotic regulator Bcl-2. The role of the tail anchor varies from protein to protein. In the case of SNAREs, for example, it is crucial for membrane fusion; in the Bcl-2 family, the tail anchor targets proteins to the mitochondrial outer membrane to control the release of apoptotic factors from the inter-membrane space [59] . The role of the ARTD15 tail anchor remains to be elucidated, but we can hypothesise that it might play a role in importin function, since we have identified Kapß1 as an ARTD15 interactor.
Kapß1 is a soluble receptor protein with a pivotal role in nuclear transport [60] . In our experiments, immunofluorescence analysis revealed that this protein co-localises with ARTD15 at the ER and the nuclear envelope. Kapß1 was recently found to associate with an ER-associated degradation (ERAD) transmembrane component (VIMP), thus supporting the hypothesis that Kapß1 plays a functional role at the ER [61] . We found that ERresident ARTD15 catalyzes mono-ADP-ribosylation of Kapß1. This mono-ADP-ribosylation has some distinguishing features: i) it does not appear to occur on arginine, cysteine or glutamate residue. Although at this time the targeted aminoacid remains unknown, based on our findings we can speculate that ARTD15-mediatedADP-ribosylation might be occurring on a serine/ threonine residue; this is at variance with the reactions catalysed by ARTC mono-ADP-ribosyltransferases and Sirt4, which specifically modify arginine and cysteine residues, respectively; ii) it is inhibited by PJ34, a well-characterized inhibitor of ARTD enzymes [55] . Since, however, PJ34 was described to act on the ß-NAD+ binding pocket of PARP1/ARTD1, we can hypothesise that it can also affect other ARTDs/PARPs having a similar NAD+ binding pocket structure, independently from whether the reaction catalyzed is a mono-or poly-ADP-ribosylation. iii) Finally, ARTD15-catalysed mono-ADP-ribosylation was not reverted by ARH1, which hydrolyzes the ADP-ribose-arginine bond, or by ARH3, which catalyzes the hydrolysis of polyADPribose and of O-acetyl-ADP-ribose (data not shown) [62, 63] . In conclusion, although the specific amino acid residue remain to be identified, the possibility exist that ARTD15 might be the first enzyme able to ADP-ribosylate a serine/threonine residue, a modification that had been described years ago [53] . Identification of the precise Kapß1 modification site will require further work and might be instrumental in defining the functional meaning of the ARTD15-Kapß1 interaction.
We suggest that ARTD15 might be a new player in the control of nuclear transport together with the nuclear pore complex, cargo proteins and karyopherins [64] . Two mechanisms have been described so far for the control of karyopherins: attenuation of protein expression and their sequestration. Indeed, it has been reported that poly-ADP-ribosylation of cargo proteins -but not of karyopherins-blocks their exit from the nucleus [65] . Mono-ADPribosylation of Kapß1 by ARTD15 might be a further level of control of nuclear transport. Future work will clarify whether ARTD15-mediated Kapß1 ADP-ribosylation can regulate Kapß1 interaction with its partners.
Materials and Methods
Cell Culture and Fractionation
Human embryonic kidney (HEK293; ATCC, CRL-1573), epidermoid carcinoma (A431; ATCC, CRL-1555), human leukemia (HL60; ATCC, CCL-240), prostate carcinoma (from a brain metastatic site; DU145; ATCC, HTB-81), ovary adenocarcinoma (SKOV-3; ATCC, HTB-77), colorectal carcinoma (HCT116; ATCC, ECL-247 and HT29; ATCC, HTB-38) and breast adenocarcinoma (MDA; ATCC, HTB-26) cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen); cervix adenocarcinoma (HeLa; ATCC, CCL-2) cells were grown in Modified Eagle's medium (MEM; Invitrogen); prostate carcinoma (from a bone metastatic site; PC3; ATCC, CRL-1435) and ovary adenocarcinoma (OVCAR-3; ATCC, HTB-161) cells were grown in RPMI medium; brain neuroblastoma (from a bone marrow metastatic site; SH-SY-5; ATCC, CRL-2266), melanoma (A375MM; obtained from Prof. Gustavo Egea, Universitat de Barcelona, Spain [66] ) and kidney (HK2; ATCC, CRL-2190) cell lines were grown in DMEM:F12 (1:1) medium (Invitrogen); all growth media were supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 10% foetal bovine serum (FBS), all from Invitrogen. Total lysates, total membranes and cytosol fractions were prepared as previously described [14, 48] . Other reagents were purchased from SigmaAldrich, unless otherwise specified.
Western Blotting and Antibodies
Cells were lysed and protein concentrations were determined with the Bio-Rad protein assay (Bio-Rad). Samples were separated by 10% SDS-PAGE and transferred to nitrocellulose filters (Perkin Elmer). Blots were incubated with primary antibodies diluted in T-TBS for 1 hour at room temperature or over-night at 4uC. After washes with T-TBS, blots were incubated in horseradish peroxidase (HRP)-conjugated secondary anti-mouse or anti-rabbit (Calbiochem) antibodies. Protein bands were visualised with the ECL-plus chemiluminescence reagent (GE Healthcare) according to manufacturer's instructions. Densitometric evaluation was carried out with the public domain ImageJ software. The following primary antibodies were used: rabbit anti-ARTD15, mouse anti-GFP and rabbit anti-calnexin (C-ter) (AbCam), mouse anticalnexin (N-ter; BD Bioscience), mouse anti-His, rabbit anti-actin, mouse anti-FLAG (Sigma-Aldrich), rabbit anti-biotin (Bethyl) and rabbit anti-GRK2 (Santa Cruz). We also used our own polyclonal antibodies against human ARTD15, rat GRASP55 and human GST, these were raised in rabbits using GST-ARTD15, His-GRASP55 and GST as immunogens, respectively. All were affinity-purified on their corresponding immunogens.
Plasmids and Transfection
The pCMV-XL5 ARTD15 eukaryotic expression vector was purchased from OriGene. The PCR product corresponding to full length ARTD15 and DTM-ARTD15 (aa 1-277) was amplified from the pCMV-XL5-ARTD15 vector using forward ARTD15-HindFor and reverse ARTD15BamRev or DTM-ARTD15BamRev primers (see Table 2 ). PCR products were gel-purified and subcloned into the HindIII (59) and BamHI (39) sites of the p3xFLAG-CMV-10, which encodes the FLAG-tag at the Nterminus. To obtain GFP-tagged constructs, the full-length ARTD15 PCR product obtained using ARTD15EcoFor and ARTD15SalRev primers (see Table 2 ) was subcloned into the EcoRI (59) and SalI (39) sites of pEGFP-C3 and pEGFP-N2 vectors (Clontech). Restriction enzymes were all from New England Biolabs. HeLa and HEK293 cells were transfected with the different cDNAs using TransIT-LT1 transfection reagent (MirusBio) according to manufacturer's instructions. To silence ARTD15, Hela cells were transfected with a pool of two siRNAs (50 nM), using Lipofectamine 2000 (Invitrogen). The following siRNAs (Qiagen) were used: 1) AACAGTCATGTTTCTCA-TAAA; 2) TACAGCTGAAATGGAACCAAA. 70% of endogenous ARTD15 was knocked down after 72 h, as evaluated by WB. As control, the following Scrambled oligos (Sigma) were used: 1) GCTTCCTACCACAATTTCT; 2) GGTAATCAACTAATCT-TAA.
Site-directed Mutagenesis
Point mutations were generated using Quik Change Sitedirected mutagenesis kits (Stratagene), following the manufacturer's instructions. Double mutagenesis was performed on the pCMV-XL5-ARTD15 plasmid, using the oligonucleotides ARTD15(H152A)For and ARTD15(H152A)Rev, and then on the pCMV-XL5-ARTD15H152A plasmid, using the oligonucleotides ARTD15(Y254A)For and ARTD15(Y254A)Rev. The oligonucleotide sequences are reported in Table 2 . The construct sequences were confirmed by automated DNA sequencing.
Protease Protection Assay
HeLa cells were plated in 12-well dishes and then transfected with pEGFP-N3-ARTD15 or pEGFP-C2-ARTD15. Twenty-four hours later, cells were washed with PBS and analyzed as previously described [58] , with minor modifications. Monolayers were either left untreated or permeabilised with digitonin (100 mg/ml) in 25 mM Tris/250 mM sucrose pH 7.4 for 1,5 minutes. The digitonin-containing solution was then removed and replaced with trypsin (120 mg/ml) in 25 mM Tris/250 mM sucrose pH 7.4 for 3 minutes. Alternatively, cells were permeabilised with 1% Triton X-100 in 25 mM Tris/250 mM sucrose pH 7.4 with trypsin (120 mg/ml) for 3 minutes. Proteolysis was blocked by adding complete protease inhibitors (Roche) at 10 fold the recommended concentration with the addition of 1 mM phenylmethylsulfonyl fluoride (PMSF). Total cell lysates were prepared in RIPA buffer, separated by SDS-PAGE and immunoblotted.
RNA Extraction
RNA was isolated from the various cell lines using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were dissolved in water and quantified with a spectrophotometer at 260 nm. Samples were treated with DNase-I (Ambion). Total RNA (2 mg) was retro-transcribed using the Enhanced Avian RT First Strand Synthesis Kit according to manufacturer's instructions (Sigma-Aldrich).
Quantitative Real-time PCR (qRT-PCR)
qRT-PCR was performed as described [67] . Primer sequences for human ARTD15 and GAPDH genes ( Table 2) were designed using Primer Express 3.0 software (Applied Biosystems). Quantitative normalization of the cDNA in each sample was carried out using glyceraldeyde-3-phosphate dehydrogenase (GAPDH, accession number: X52123.1) amplification as internal control. Relative quantification was done using the comparative DC T method.
Recombinant Protein Purification
To obtain the N-terminally GST-tagged construct, purified fulllength ARTD15 and ARTD15-H152A/Y254A (ARTD15-dm) PCR products were subcloned into the pGEX-4T1 vector (GE Healthcare) using the EcoRI (59) and SalI (39) sites. The pQE60-Kapß1 vector encoding full-length His-Kapß1 was kindly provided by Prof. Gino Cingolani (Department of Biochemistry and Molecular Biology, Jefferson Medical College, Philadelphia, USA). For GST-ARTD15 (wt and dm) production, transformed DH5a cells were grown in Luria-Bertani medium at 37uC, induced with 0.1 mM isopropyl-d-thiogalactoside (IPTG), and grown for a further 16-20 h at 20uC. Purification of recombinant GST-tagged ARTD15 (wt and dm) from the soluble lysate protein was accomplished with Glutathione Sepharose 4B resin (GE Healthcare) following the manufacturer's instructions. For HisKapß1 purification transformed BL21 (DE3) cells (Novagen) were grown in Luria-Bertani medium at 37uC, induced with 0.5 mM IPTG, and grown for a further 16-20 hours at 37uC. Purification of recombinant His-tagged Kapß1 protein from the soluble lysate protein was accomplished with the Ni-NTA (Qiagen) affinity resin following the manufacturer's instructions.
Immunoprecipitation, GST-pull-down and MALDI-ToF Analysis
HeLa or HEK293 cells were transfected with FLAG-ARTD15. After 24 hours, cells were lysed in IP buffer (25 mM Tris-Hcl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 5 mM MgCl2, 1 mM DTT, 1 mM NaVO4, 40 mM ß-glycerophosphate) with protease inhibitors. The lysates were collected and centrifuged at 10.000 g for 10 min at 4uC. The supernatants were then diluted to 0.2% Triton X-100 final concentration. For ARTD15 immunoprecipitation, total lysates from HeLa or HEK293 cells (6 mg) were incubated over-night at 4uC with constant rotation with anti-FLAG antibody (0.5 mg/mg lysate) or control IgG. The samples were then incubated with a 50% protein-A sepharose resin slurry for 2 h at 4uC with constant rotation. Resins were centrifuged, washed five times and eluted with Laemmli buffer. Eluates were separated by SDS-PAGE and analysed by Silver staining. Differential protein bands were cut, trypsinised and analysed by MALDI-TOF mass spectrometry. For Kapß1 immunoprecipitation, total lysates (2 mg) from HeLa cells over-expressing FLAG-ARTD15 were incubated with an antiKapß1 antibody (1 mg/mg lysate) or with the same amount of control IgG over-night at 4uC with constant rotation. The day after, the samples were incubated with 50 ml of a 50% protein-A sepharose resin slurry for 2 h at 4uC with constant rotation. The samples were then centrifuged and resins were washed 5 times in IP buffer with 0.2% Triton X-100, and one time using IP buffer without detergent. Resins were then eluted with 100 ml of Laemmli buffer, boiled for 5 minutes at 100uC and separated by 12% SDS-PAGE. Proteins were transferred to nitrocellulose membrane for immunoblotting.
The GST-pull-down experiments were performed as previously described (Cai et al., 2007) . Briefly, His-Kapß1 was incubated over-night at 4uC with GST or GST-ARTD15 protein in binding buffer (50 mM Tris-Hcl, pH 7.4, 100 mM NaCl, 0.1% Triton X-100, 0.1% NP-40 and 1 mg/ml BSA). The samples were then incubated with a 50% Glutathione Sepharose 4B resin slurry for 2 h at 4uC with constant rotation and centrifuged at 500 g for 5 minutes. The resin was washed 5 times with washing buffer (50 mM Tris-Hcl, pH 7.4, 100 mM NaCl) and eluted with Laemmli buffer. The eluates were analysed by SDS-PAGE and Western Blot.
ADP-ribosylation Assay, Thin Layer Chromatography (TLC) and ADP-ribosylation Product Analysis ARTD15 activity was measured by using a previously described [ 32 P]-ADP-ribosylation assay [14, 48] . ADP-ribosylation with biotin-NAD (25 mM; 6-biotin-17-NAD Trevigen) was performed as previously described [68] . The kinetic parameters were determined by incubating 300 ng of purified GST-ARTD15 with a fixed amount of [ 32 P]-NAD + (2 mCi) and increasing concentration of cold NAD (1-1000 mM) for 16 h at 37uC. The [ 32 P]-ADPribosylated ARTD15 was quantified with an InstantImager (Packard Instrument Co). Thin-layer chromatography was performed as described [67] . Nucleotide were released from ADPribosylated proteins as described previously [54, 69] with a minor modification: the TCA-precipitated samples were incubated in 100 ml of 10 mM Tris-NaOH, pH 12, 1 mM EDTA and 0,2 mg/ ml proteinase K at 60uC for 3 hours. The length of ADPribosylation products was analysed by high-resolution gel electrophoresis, as described previously [54] .
ADP-ribose Bond Stability
ADP-ribose-ARTD15 bond stability was examined as described previously [70] , with minor modifications. GST-ARTD15 was [ 32 P]-ADP-ribosylated and electroblotted; radioactivity on the filter was quantified with an InstantImager. The filter was then divided into separate strips, each of which was incubated with 50 mM Hepes, 1% SDS containing either 1 mM HgCl 2 at 37uC for 1 hour, or 0.5 M NH 2 OH at 37uC for 20 minutes, or 1 M NH 2 OH at 37uC for 12 hours, or 0.2 M HCl at 37uC for 2 hours or 1 M NaCl at 37uC for 12 hours. After treatments the filters were washed twice with water for 5 minutes and analyzed with an InstantImager.
Indirect Immunofluorescence and Antibodies
HeLa cells were grown on coverslips in 24-well plates and transfected with TransIT-LT1 (MirusBio, USA). Immunofluorescence was performed as described [67] ; using an anti-FLAG antibody (ANTI-FLAGH M2 antibody, F3165 Sigma; 1:500 in blocking solution) and an anti-ARTD15 antibody (AbCam; 1:50 in blocking solution) to stain ARTD15. Anti-PDI (SPA-891 Stressgen; 1:200 in blocking solution); anti-calnexin (BD Bioscience; 1:200 in blocking solution); and anti-Kapß1 (AbCam; 1:500 in blocking solution) antibodies were also used as primary antibodies. Alexa 488-and Alexa 546-conjugated goat anti-rabbit and antimouse IgG (Molecular Probes; 1:400 in blocking buffer) were used as secondary antibodies. Samples were analysed using a confocal microscope (Zeiss LSM 510).
Electron Microscopy
HeLa cells transfected with FLAG-ARTD15 were used for immuno-EM analysis using the gold-enhance protocol [71] and cut as described previously [72] . Briefly, cells were fixed with 4% formaldehyde and 0.05% glutaraldehyde for 10 min at 37uC, and postfixed for 30 min with 4% formaldehyde alone, at room temperature. After washing with PBS and a 20-min treatment with a blocking solution containing 1% bovine serum albumin, 50 mM NH4Cl and 0.2% saponin, samples were incubated with a primary rabbit anti-FLAG antibody for 1 h. Samples were then incubated for 2 h with nanogold-conjugated anti-rabbit IgG (Nanoprobes) diluted in blocking solution (1:100) and extensively washed. Gold particles were enhanced with Gold Enhancer (Nanoprobes), according to the manufacturer's instructions. Samples were then fixed with 1% glutaraldehyde in 0.15 M HEPES (pH 7.3) at 37uC for 5 min. After fixation, the cells were scraped and collected in 1.5 ml tubes. Collected cells were centrifuged and treated with 1% OsO4 plus 1.5% potassium ferrocyanide in 0.1 M cacodylate buffer (pH 7.3) for 1.5 h at room temperature in the dark. Samples were then dehydrated by consecutive washes with ethanol at increasing concentrations (50%-70%-90%-100%) and finally embedded in Epon 812. Finally, samples were examined on a Tecnai 12 electron microscope at 120 kW (FEI/Philips Electron Optics).
